Meeting
2014 Gastrointestinal Cancers Symposium
FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study.
Authors
Howard Safran
Brown University Oncology Research Group, Providence, RI
Howard Safran , Kevin Charpentier , Kimberly Perez , Kalyan Mantripragada , Trevor Clark Austin , Omar Nadeem , Alise Lombardo , Lindsay Houlihan , Lucia Fontes-Borts , Irene Kolberg , Kristen Mitchell , Kayla Rosati
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01744353
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 258)
DOI
10.1200/jco.2014.32.3_suppl.258
Abstract #
258
Poster Bd #
B31
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2024 ASCO Annual Meeting
Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial.
First Author: Choong-kun Lee
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research Consortium—BTCRC-GI15-015.
First Author: Al Bowen Benson III